Anti-IL-1RA Antibody - BSA and Azide free (A283296)

Anti-IL-1RA Antibody - BSA and Azide free

Rabbit polyclonal antibody to IL-1RA.

This antibody recognises human Interleukin-1 receptor antagonist (IL-1RA), a naturally occurring inflammatory inhibitor protein, produced by monocytes, macrophages, neutrophils, corneal epithelial cells and fibroblasts, which inhibits the activity of IL-1 alpha and IL-1 beta, by competitively blocking binding to cell surface receptors for IL-1.Genetic variations in IL-1RA gene (IL1RN) are associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4), and IL-1RA has therapeutic applications in rheumatoid arthritis, asthma, psoriasis, sepsis, chronic myelogenous leukaemia and inflammatory bowel disease.

WB, ELISA, Functional Assays

ELISA: 0.5 - 2 µg/ml, Functional Assays: 2.5 - 3.7 µg/ml, WB: 0.1 - 0.2 µg/ml

Human

Recombinant human IL-1RA.

Rabbit

Polyclonal

IgG

1 mg/ml after reconstitution.

Reconstitute with 0.1 ml of distilled water. Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Gently mix after reconstitution. For long term storage the addition of 0.09% sodium azide is recommended. For functional studies do not add sodium azide

Supplied in Phosphate Buffered Saline.

Lyophilized: Store at -20°C. Reconstituted: Store undiluted at -20°C, avoid freeze / thaw cycles. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.

Rabbit anti Human interleukin-1 receptor antagonist antibody recognises human Interleukin-1 receptor antagonist (IL-1RA), a naturally occurring inflammatory inhibitor protein, produced by monocytes, macrophages, neutrophils, corneal epithelial cells and fibroblasts, which inhibits the activity of IL-1 alpha and IL-1 beta, by competitively blocking binding to cell surface receptors for IL-1. Genetic variations in IL-1RA gene (IL1RN) are associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4), and IL-1RA has therapeutic applications in rheumatoid arthritis, asthma, psoriasis, sepsis, chronic myelogenous leukaemia and inflammatory bowel disease.

CD210, CDw210a, ICIL-1RA, IL-10 receptor subunit alpha, IL-10R subunit 1, IL-10R subunit alpha, IL-10R1, IL-10RA, IL-1RN, IL1 inhibitor, IL10R, IL10RA, IL1F3, IL1RA, IL1RN, Interleukin-1 receptor antagonist protein, Interleukin-10 receptor subunit 1, Interleukin-10 receptor subunit alpha, IRAP